Produktname:5-Bromo-2-fluoropyridine

IUPAC Name:5-bromo-2-fluoropyridine

CAS:766-11-0
Molekulare Formel:C5H3BrFN
Reinheit:95%+
Katalognummer:CM120561
Molekulargewicht:175.99

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM120561-500g in stock ŭƅş

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:766-11-0
Molekulare Formel:C5H3BrFN
Schmelzpunkt:-
SMILES-Code:FC1=NC=C(Br)C=C1
Dichte:
Katalognummer:CM120561
Molekulargewicht:175.99
Siedepunkt:
Mdl-Nr.:MFCD01863742
Lagerung:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Tirbanibulin
Actinic keratosis (AK) is a chronic disease resulting from deleterious effects of long-term, cumulative, epidermal exposure to ultraviolet (UV) light. 
Tirbanibulin is a synthetic, first-in-class, potent anti-proliferative agent that has shown antiproliferative and antitumoral effects in vitro and in vivo by inducing cell cycle arrest and ultimately apoptotic cell death. These effects have been attributed to the ability of tirbanibulin to reversibly bind to the colchicine-binding site on b-tubulin and inhibit tubulin microfilament polymerization.
The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033, growing at a CAGR of 3.04% from 2024 to 2033.